{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T23:18:58Z","timestamp":1792883938587,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.vaccine.2025.127301","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T20:51:53Z","timestamp":1748638313000},"page":"127301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Sample size efficiency of restricting participation in tuberculosis vaccine trials to interferon-gamma release assay-positive participants"],"prefix":"10.1016","volume":"61","author":[{"given":"Frank","family":"Cobelens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puck T.","family":"Pelzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin J.","family":"Churchyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Garcia-Basteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hatherill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127301_bb0010","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1473-3099(19)30003-9","article-title":"A new tuberculosis vaccine: breakthrough, challenges, and a call for collaboration","volume":"19","author":"Vekemans","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127301_bb0015","author":"TB Vaccine Clinical Pipeline"},{"key":"10.1016\/j.vaccine.2025.127301_bb0020","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S1473-3099(21)00810-0","article-title":"Accelerating research and development of new vaccines against tuberculosis: a global roadmap","volume":"22","author":"Cobelens","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127301_bb0025","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/infdis\/jiad356","article-title":"An aspiration to radically shorten phase 3 tuberculosis Vaccine trials","volume":"228","author":"Hill","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127301_bb0030","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.3389\/fmicb.2019.03154","article-title":"Clinical development of new TB vaccines: recent advances and next steps","volume":"10","author":"Hatherill","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2025.127301_bb0035","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S1473-3099(20)30276-0","article-title":"Interferon-\u03b3 release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis","volume":"20","author":"Zhou","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127301_bb0040","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1164\/rccm.201206-1134OC","article-title":"Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents","volume":"186","author":"Machingaidze","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2025.127301_bb0045","series-title":"Epidemiologic basis of tuberculosis control","author":"Rieder","year":"1999"},{"key":"10.1016\/j.vaccine.2025.127301_bb0050","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/S1473-3099(22)00153-0","article-title":"Are we underestimating the annual risk of infection with mycobacterium tuberculosis in high-burden settings?","volume":"22","author":"Dowdy","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127301_bb0055","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S0950268897007917","article-title":"The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection","volume":"119","author":"Vynnycky","year":"1997","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2025.127301_bb0060","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/cid\/cir951","article-title":"Risk of progression to active tuberculosis following reinfection with mycobacterium tuberculosis","volume":"54","author":"Andrews","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127301_bb0065","series-title":"An introduction to infectious disease modelling","author":"Vynnycky","year":"2010"},{"key":"10.1016\/j.vaccine.2025.127301_bb0070","first-page":"308","article-title":"The evolution of clinical tuberculosis in adolescents","volume":"47","author":"Sutherland","year":"1966","journal-title":"Tubercle"},{"key":"10.1016\/j.vaccine.2025.127301_bb0075","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1164\/rccm.201905-0969OC","article-title":"Quantitative IFN-\u03b3 release assay and tuberculin skin test results to predict incident tuberculosis. A prospective cohort study","volume":"201","author":"Gupta","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2025.127301_bb0080","article-title":"Prevalence of mycobacterium tuberculosis infection as measured by the QuantiFERON-TB gold assay and ESAT-6 free IGRA among adolescents in Mwanza","volume":"16","author":"Jeremiah","year":"2021","journal-title":"Tanzania PLoS One"},{"key":"10.1016\/j.vaccine.2025.127301_bb0085","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1186\/s12879-019-4314-7","article-title":"Estimating the annual risk of infection with mycobacterium tuberculosis among adolescents in Western Kenya in preparation for TB vaccine trials","volume":"19","author":"Nduba","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127301_bb0090","article-title":"Effectiveness of the primary Bacillus Calmette-Gu\u00e9rin vaccine against the risk of mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data","author":"Pelzer","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2025.127301_bb0095","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127301_bb0100","first-page":"406","article-title":"Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa","volume":"14","author":"Wood","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.vaccine.2025.127301_bb0105","first-page":"156","article-title":"Age- and sex-specific social contact patterns and incidence of mycobacterium tuberculosis infection","volume":"183","author":"Dodd","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2025.127301_bb0110","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/ije\/dyr058","article-title":"The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach","volume":"40","author":"Borgdorff","year":"2011","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2025.127301_bb0115","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1164\/rccm.201406-1159OC","article-title":"Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam","volume":"190","author":"Sloot","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2025.127301_bb0120","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/AS01E Vaccine to prevent tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127301_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/b371be66-de38-4ed6-b440-d27c9d7e552c","article-title":"The tuberculin skin test versus QuantiFERON TB gold\u00ae in predicting tuberculosis disease in an adolescent cohort study in South Africa","volume":"6","author":"Mahomed","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127301_bb0130","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1471-2334-11-156","article-title":"Force of tuberculosis infection among adolescents in a high HIV and TB prevalence community: a cross-sectional observation study","volume":"11","author":"Middelkoop","year":"2011","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127301_bb0135","doi-asserted-by":"crossref","first-page":"571","DOI":"10.5588\/ijtld.18.0283","article-title":"Temporal trends in the prevalence of mycobacterium tuberculosis infection in south African adolescents","volume":"23","author":"Bunyasi","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.vaccine.2025.127301_bb0140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tube.2005.06.001","article-title":"The search for a tuberculosis vaccine: an elusive quest?","volume":"86","author":"Nagelkerke","year":"2006","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.vaccine.2025.127301_bb0145","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/infdis\/jir162","article-title":"Epidemiologic inference from the distribution of tuberculosis cases in households in Lima","volume":"203","author":"Brooks-Pollock","year":"2011","journal-title":"Peru J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127301_bb0150","doi-asserted-by":"crossref","first-page":"e684","DOI":"10.1016\/S2214-109X(23)00082-7","article-title":"Quantifying progression and regression across the spectrum of pulmonary tuberculosis: a data synthesis study","volume":"11","author":"Richards","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2025.127301_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096433","article-title":"Tobacco smoking, alcohol drinking, diabetes, low body mass index and the risk of self-reported symptoms of active tuberculosis: individual participant data (IPD) meta-analyses of 72,684 individuals in 14 high tuberculosis burden countries","volume":"9","author":"Patra","year":"2014","journal-title":"PLoS One"},{"issue":"25","key":"10.1016\/j.vaccine.2025.127301_bb0160","first-page":"00144","article-title":"Trajectories of interferon-gamma release assay results over 2 years in independent cohorts from China, South Africa, Tanzania, and the United States","volume":"S0012-3692","author":"Chen","year":"2025","journal-title":"Chest"},{"key":"10.1016\/j.vaccine.2025.127301_bb0165","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S2213-2600(23)00084-X","article-title":"Clinical trials of tuberculosis vaccines in the era of increased access to preventive antibiotic treatment","volume":"11","author":"Rangaka","year":"2023","journal-title":"Lancet Respir Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25005985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25005985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T21:20:52Z","timestamp":1755897652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25005985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":32,"alternative-id":["S0264410X25005985"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127301","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sample size efficiency of restricting participation in tuberculosis vaccine trials to interferon-gamma release assay-positive participants","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127301"}}